Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $19.24 in the prior trading day, Cellebrite DI Ltd (NASDAQ: CLBT) closed at $18.88, down -1.87%. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 0.77 million shares were traded. CLBT stock price reached its highest trading level at $19.37 during the session, while it also had its lowest trading level at $18.805.
Ratios:
Our goal is to gain a better understanding of CLBT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.24. For the most recent quarter (mrq), Quick Ratio is recorded 2.08 and its Current Ratio is at 2.11. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously. BofA Securities Upgraded its Neutral to Buy on February 16, 2024, whereas the target price for the stock was revised from $9 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when SHAPIRA AYALA BERLER bought 8,448 shares for $18.05 per share.
DAVID GEE bought 1,969 shares of CLBT for $33,237 on Nov 24 ’25. On Nov 21 ’25, another insider, DAVID GEE, who serves as the OFFICER of the company, bought 3,704 shares for $17.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 4615576576 and an Enterprise Value of 4093173248. As of this moment, Cellebrite’s Price-to-Earnings (P/E) ratio for their current fiscal year is 61.72, and their Forward P/E ratio for the next fiscal year is 47.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.92 while its Price-to-Book (P/B) ratio in mrq is 11.07. Its current Enterprise Value per Revenue stands at 8.978 whereas that against EBITDA is 56.806.
Stock Price History:
The Beta on a monthly basis for CLBT is 1.28, which has changed by -0.1452688 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, CLBT has reached a high of $26.30, while it has fallen to a 52-week low of $13.10. The 50-Day Moving Average of the stock is 6.32%, while the 200-Day Moving Average is calculated to be 9.38%.
Shares Statistics:
The stock has traded on average 1.32M shares per day over the past 3-months and 1185030 shares per day over the last 10 days, according to various share statistics. A total of 239.47M shares are outstanding, with a floating share count of 114.18M. Insiders hold about 52.32% of the company’s shares, while institutions hold 46.83% stake in the company. Shares short for CLBT as of 1764288000 were 5227810 with a Short Ratio of 3.95, compared to 1761868800 on 6331271. Therefore, it implies a Short% of Shares Outstanding of 5227810 and a Short% of Float of 4.33.
Earnings Estimates
The stock of Cellebrite DI Ltd (CLBT) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.11, with high estimates of $0.13 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.54 and $0.47 for the fiscal current year, implying an average EPS of $0.51. EPS for the following year is $0.55, with 8.0 analysts recommending between $0.61 and $0.46.
Revenue Estimates
8 analysts predict $126.07M in revenue for. The current quarter. It ranges from a high estimate of $128M to a low estimate of $123.17M. As of. The current estimate, Cellebrite DI Ltd’s year-ago sales were $109.05MFor the next quarter, 8 analysts are estimating revenue of $125.2M. There is a high estimate of $128M for the next quarter, whereas the lowest estimate is $121.87M.
A total of 8 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $475M, while the lowest revenue estimate was $470.03M, resulting in an average revenue estimate of $472.92M. In the same quarter a year ago, actual revenue was $401.2MBased on 8 analysts’ estimates, the company’s revenue will be $554.5M in the next fiscal year. The high estimate is $569.1M and the low estimate is $540M.
